Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients
Douglas D. Fraser(Western University), Eleftherios P. Diamandis(Lunenfeld-Tanenbaum Research Institute), Michael R. Miller(Western University), Gediminas Cepinskas(Western University), David B. O’Gorman(Western University), Claudio M. Martin(Western University), Eric K. Patterson(Lawson Health Research Institute), Guillaume Paré(Impact), Mark Daley(Western University), Maitray A. Patel(Western University), Sean E. Gill(Western University), Marat Slessarev(Western University), Ioannis Prassas(University Health Network)
Cited by 82
Related Papers
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
|New England Journal of Medicine|1999|5.2k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study
|Intensive Care Medicine|2001|984
New loci associated with kidney function and chronic kidney disease
|Nature Genetics|2010|809